Insider trade

CEO sold ~$315K of UTHR shares in the open market

Traded Mar 19, 2026 · Filed Mar 21, 2026

Why it stands out

The CEO of United Therapeutics sold $315K of United Therapeutics shares. The filing says it was made under a pre-arranged trading plan.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

CEO$100K–$500KPre-arranged plan referenced

Classification

open market sale

Code S — open-market or private sale

Absolute commitment

~$314,524

Shares × reported transaction price

Timing vs results

22 days after results of Feb 25, 2026, 48 days before results of May 6, 2026

Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results

Planned / mechanical clue

Footnote references a pre-arranged trading plan (Rule 10b5-1)

Only flagged when a footnote says so; never inferred

After	Stock	S&P 500	Difference
7 days	+12.9%	−3.6%	+16.4%
30 days	+10.2%	+8.5%	+1.7%
90 days	+3.3%	+13.6%	−10.3%
180 days	−5.4%	+18.0%	−23.4%

Past results only. Not a forecast.

This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 17, 2027; or (b) December 31, 2026.
This transaction was executed in multiple trades at prices ranging from $524.62 to $525.61. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.